Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 5;4(10):100529.
doi: 10.1016/j.jhepr.2022.100529. eCollection 2022 Oct.

Role of precipitants in transition of acute decompensation to acute-on-chronic liver failure in patients with HBV-related cirrhosis

Tongyu Wang  1   2 , Wenting Tan  3 , Xianbo Wang  4 , Xin Zheng  5 , Yan Huang  6 , Beiling Li  7 , Zhongji Meng  8 , Yanhang Gao  9 , Zhiping Qian  10 , Feng Liu  11   12 , Xiaobo Lu  13 , Huadong Yan  14 , Yubao Zheng  15 , Weituo Zhang  16 , Shan Yin  1   2 , Wenyi Gu  1   2   17   18 , Yan Zhang  1   2 , Fuchen Dong  1   2 , Jianyi Wei  1   2 , Guohong Deng  3 , Xiaomei Xiang  3 , Yi Zhou  3 , Yixin Hou  4 , Qun Zhang  4 , Shue Xiong  5 , Jing Liu  5 , Liyuan Long  6 , Ruochan Chen  6 , Jinjun Chen  7 , Xiuhua Jiang  7 , Sen Luo  8 , Yuanyuan Chen  8 , Chang Jiang  9 , Jinming Zhao  9 , Liujuan Ji  10 , Xue Mei  10 , Jing Li  12 , Tao Li  12 , Rongjiong Zheng  13 , Xinyi Zhou  13 , Haotang Ren  19   20   21 , Yu Shi  19   20   21 , Hai Li  1   2 ; Chinese (Acute on) Chronic Liver Failure Consortium (Ch-CLIF.C)
Affiliations

Role of precipitants in transition of acute decompensation to acute-on-chronic liver failure in patients with HBV-related cirrhosis

Tongyu Wang et al. JHEP Rep. .

Abstract

Background & aims: Pre-acute-on-chronic liver failure (ACLF) is a distinct intermediate stage between acute decompensation (AD) and ACLF. However, identifying patients with pre-ACLF and predicting progression from AD to ACLF is difficult. This study aimed to identify pre-ACLF within 28 days, and to develop and validate a prediction model for ACLF in patients with HBV-related decompensated cirrhosis.

Methods: In total, 1,736 patients with HBV-related cirrhosis and AD were enrolled from 2 large-scale, multicenter, prospective cohorts. ACLF occurrence within 28 days, readmission, and 3-month and 1-year outcomes were collected.

Results: Among 970 patients with AD without ACLF in the derivation cohort, the 94 (9.6%) patients with pre-ACLF had the highest 3-month and 1-year LT-free mortality (61.6% and 70.9%, respectively), which was comparable to those with ACLF at enrollment (57.1% and 67.1%); the 251 (25.9%) patients with unstable decompensated cirrhosis had mortality rates of 22.4% and 32.1%, respectively; while the 507 (57.9%) patients with stable decompensated cirrhosis had the best outcomes (1-year mortality rate of 2.6%). Through Cox proportional hazard regression, specific precipitants, including hepatitis B flare with HBV reactivation, spontaneous hepatitis B flare with high viral load, superimposed infection on HBV, and bacterial infection, were identified to be significantly associated with ACLF occurrence in the derivation cohort. A model that incorporated precipitants, indicators of systemic inflammation and organ injuries reached a high C-index of 0.90 and 0.86 in derivation and validation cohorts, respectively. The optimal cut-off value (0.22) differentiated high-risk and low-risk patients, with a negative predictive value of 0.95.

Conclusions: Three distinct clinical courses of patients with AD are validated in the HBV-etiology population. The precipitants significantly impact on AD-ACLF transition. A model developed by the precipitant-systemic inflammation-organ injury framework could be a useful tool for predicting ACLF occurrence.

Clinical trial number: NCT02457637 and NCT03641872.

Lay summary: It was previously shown that patients with decompensated cirrhosis could be stratified into 3 groups based on their short-term clinical prognoses. Herein, we showed that this stratification applies to patients who develop cirrhosis as a result of hepatitis B virus infection. We also developed a precipitant-based model (i.e. a model that incorporated information about the exact cause of decompensation) that could predict the likelihood of these patients developing a very severe liver disease called acute-on-chronic liver failure (or ACLF).

Keywords: ACLF, acute-on-chronic liver failure; AD, acute decompensation; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CATCH-LIFE study, Chinese AcuTe-On-Chronic LIver FailurE Study; CLIF, Chronic Liver Failure; CLIF-C AD, CLIF consortium acute decompensation score; CRP, C-reactive protein; EASL, European Association for the Study of the Liver; HR, hazard ratio; INR, international normalized ratio; LT, liver transplantation; MELD, model for end-stage liver disease; NL, neutrophil-lymphocyte ratio; NPV, negative predictive value; OFs, organ failures; PPV, positive predictive value; PVT, portal vein thrombosis; SDC, stable decompensated cirrhosis; UDC, unstable decompensated cirrhosis; WBC, white blood cell; acute-on-chronic liver failure; acutely decompensated cirrhosis; hepatitis B virus; iMELD, integrated MELD; precipitants; prediction model.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.

Figures

None
Graphical abstract
Fig. 1
Fig. 1
Patient screening flow chart according to diagnosis of ACLF and 3-month readmission in the derivation and validation cohort. ACLF, acute-on-chronic liver failure; LT, liver transplantation.
Fig. 2
Fig. 2
The discrimination and calibration plot of the ACLF development prediction model. (A) ROC curve (solid line) and AUC (95%CI) (shadow area) of the model predicting ACLF development in derivation cohort; (B) ROC curve and AUC (95% CI) of the model predicting ACLF development in the validation cohort; (C) Calibration plot in the derivation cohort; (D) Calibration plot in the validation cohort. ACLF, acute-on-chronic liver failure.
Fig. 3
Fig. 3
Predictive ability comparison between ACLF development predicting model and other prognostic scores. (A) The ROC curves of the new model and CLIF-C AD, iMELD, MELD-sodium, and Child-Pugh score comparison in the derivation cohort. (B) The ROC curves of the new model and CLIF-C AD, iMELD, MELD-sodium, and Child-Pugh score comparison in the validation cohort. ACLF, acute-on-chronic liver failure; AD, acute decompensation; CLIF-C AD, CLIF consortium acute decompensation score; iMELD, integrated MELD; MELD, model for end-stage liver disease.
Fig. 4
Fig. 4
Differentiating patients at a high risk and low risk of ACLF development with the selected cut-off in the validation cohort. The cut-off value of 0.22 covers 12% of patients as the high-risk group and 88% as the low-risk group, with a sensitivity of 0.5 and specificity of 0.92. The risks of ACLF development in the high- and low-risk groups were 39.6% and 5.3%, respectively. ACLF, acute-on-chronic liver failure.
See this image and copyright information in PMC

Comment in

Similar articles

  • The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology.
    Trebicka J, Fernandez J, Papp M, Caraceni P, Laleman W, Gambino C, Giovo I, Uschner FE, Jimenez C, Mookerjee R, Gustot T, Albillos A, Bañares R, Janicko M, Steib C, Reiberger T, Acevedo J, Gatti P, Bernal W, Zeuzem S, Zipprich A, Piano S, Berg T, Bruns T, Bendtsen F, Coenraad M, Merli M, Stauber R, Zoller H, Ramos JP, Solè C, Soriano G, de Gottardi A, Gronbaek H, Saliba F, Trautwein C, Özdogan OC, Francque S, Ryder S, Nahon P, Romero-Gomez M, Van Vlierberghe H, Francoz C, Manns M, Garcia E, Tufoni M, Amoros A, Pavesi M, Sanchez C, Curto A, Pitarch C, Putignano A, Moreno E, Shawcross D, Aguilar F, Clària J, Ponzo P, Jansen C, Vitalis Z, Zaccherini G, Balogh B, Vargas V, Montagnese S, Alessandria C, Bernardi M, Ginès P, Jalan R, Moreau R, Angeli P, Arroyo V; PREDICT STUDY group of the EASL-CLIF Consortium. Trebicka J, et al. J Hepatol. 2020 Oct;73(4):842-854. doi: 10.1016/j.jhep.2020.06.013. Epub 2020 Jul 13. J Hepatol. 2020. PMID: 32673741
  • Transplantation for EASL-CLIF and APASL acute-on-chronic liver failure (ACLF) patients: The TEA cohort to evaluate long-term post-Transplant outcomes.
    Xia L, Qiao ZY, Zhang ZJ, Lv ZC, Tong H, Tong Y, Wu HX, Chen XS, Sun HY, Zhang JJ, Thasler WE, Feng H, Xia Q. Xia L, et al. EClinicalMedicine. 2022 Jun 4;49:101476. doi: 10.1016/j.eclinm.2022.101476. eCollection 2022 Jul. EClinicalMedicine. 2022. PMID: 35747194 Free PMC article.
  • PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis.
    Trebicka J, Fernandez J, Papp M, Caraceni P, Laleman W, Gambino C, Giovo I, Uschner FE, Jansen C, Jimenez C, Mookerjee R, Gustot T, Albillos A, Bañares R, Jarcuska P, Steib C, Reiberger T, Acevedo J, Gatti P, Shawcross DL, Zeuzem S, Zipprich A, Piano S, Berg T, Bruns T, Danielsen KV, Coenraad M, Merli M, Stauber R, Zoller H, Ramos JP, Solé C, Soriano G, de Gottardi A, Gronbaek H, Saliba F, Trautwein C, Kani HT, Francque S, Ryder S, Nahon P, Romero-Gomez M, Van Vlierberghe H, Francoz C, Manns M, Garcia-Lopez E, Tufoni M, Amoros A, Pavesi M, Sanchez C, Praktiknjo M, Curto A, Pitarch C, Putignano A, Moreno E, Bernal W, Aguilar F, Clària J, Ponzo P, Vitalis Z, Zaccherini G, Balogh B, Gerbes A, Vargas V, Alessandria C, Bernardi M, Ginès P, Moreau R, Angeli P, Jalan R, Arroyo V; PREDICT STUDY group of the EASL-CLIF CONSORTIUM. Trebicka J, et al. J Hepatol. 2021 May;74(5):1097-1108. doi: 10.1016/j.jhep.2020.11.019. Epub 2020 Nov 20. J Hepatol. 2021. PMID: 33227350
  • Acute-on-Chronic Liver Failure: Recent Concepts.
    Moreau R, Jalan R, Arroyo V. Moreau R, et al. J Clin Exp Hepatol. 2015 Mar;5(1):81-5. doi: 10.1016/j.jceh.2014.09.003. Epub 2014 Oct 3. J Clin Exp Hepatol. 2015. PMID: 25941435 Free PMC article. Review.
  • Prognostic assessment of liver cirrhosis and its complications: current concepts and future perspectives.
    Gülcicegi DE, Goeser T, Kasper P. Gülcicegi DE, et al. Front Med (Lausanne). 2023 Sep 14;10:1268102. doi: 10.3389/fmed.2023.1268102. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37780566 Free PMC article. Review.
See all similar articles

Cited by

See all "Cited by" articles

References

    1. Sepanlou S.G., Safiri S., Bisignano C., Ikuta K.S., Merat S., Saberifiroozi M., et al. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5(3):245–266. - PMC - PubMed
    1. Jepsen P., Younossi Z.M. The global burden of cirrhosis: a review of disability-adjusted life-years lost and unmet needs. J Hepatol. 2021;75(Suppl 1):S3–S13. - PubMed
    1. European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406–460. - PubMed
    1. Asrani S.K., Devarbhavi H., Eaton J., Kamath P.S. Burden of liver diseases in the world. J Hepatol. 2019;70(1):151–171. - PubMed
    1. Trebicka J., Fernandez J., Papp M., Caraceni P., Laleman W., Gambino C., et al. The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. J Hepatol. 2020;73(4):842–854. - PubMed

Associated data